RU2017133093A - Кристаллические формы соединения пирролопиридина - Google Patents
Кристаллические формы соединения пирролопиридина Download PDFInfo
- Publication number
- RU2017133093A RU2017133093A RU2017133093A RU2017133093A RU2017133093A RU 2017133093 A RU2017133093 A RU 2017133093A RU 2017133093 A RU2017133093 A RU 2017133093A RU 2017133093 A RU2017133093 A RU 2017133093A RU 2017133093 A RU2017133093 A RU 2017133093A
- Authority
- RU
- Russia
- Prior art keywords
- aminopiperidin
- cyclopropanecarboxamide
- pyrrolo
- pyridin
- bromo
- Prior art date
Links
- -1 PYRROLOPYRIDINE COMPOUND Chemical class 0.000 title claims 6
- BAZRWWGASYWYGB-SNVBAGLBSA-N n-[4-[(3r)-3-aminopiperidin-1-yl]-5-bromo-1h-pyrrolo[2,3-b]pyridin-3-yl]cyclopropanecarboxamide Chemical compound C1[C@H](N)CCCN1C1=C(Br)C=NC2=C1C(NC(=O)C1CC1)=CN2 BAZRWWGASYWYGB-SNVBAGLBSA-N 0.000 claims 38
- 239000012453 solvate Substances 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 206010009944 Colon cancer Diseases 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims 9
- 239000012623 DNA damaging agent Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 238000000113 differential scanning calorimetry Methods 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 6
- 238000001757 thermogravimetry curve Methods 0.000 claims 6
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims 4
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims 4
- 229940127093 camptothecin Drugs 0.000 claims 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 4
- 229960004117 capecitabine Drugs 0.000 claims 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 4
- 229960004316 cisplatin Drugs 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 4
- 229960005277 gemcitabine Drugs 0.000 claims 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 4
- 229960004768 irinotecan Drugs 0.000 claims 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229960004964 temozolomide Drugs 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims 2
- HAFWELDDNUXLCK-TYYBGVCCSA-N (e)-but-2-enedioic acid;hydrate Chemical compound O.OC(=O)\C=C\C(O)=O HAFWELDDNUXLCK-TYYBGVCCSA-N 0.000 claims 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 claims 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- DPKGTLUCCMJBQI-UHFFFAOYSA-N ethane-1,2-disulfonic acid;hydrate Chemical compound O.OS(=O)(=O)CCS(O)(=O)=O DPKGTLUCCMJBQI-UHFFFAOYSA-N 0.000 claims 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical class OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 claims 1
- ZYNNVAZLFGFFLF-UHFFFAOYSA-N ethanesulfonic acid hydrate Chemical compound O.CCS(O)(=O)=O.CCS(O)(=O)=O ZYNNVAZLFGFFLF-UHFFFAOYSA-N 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- ZUVAACFIEPYYOP-UHFFFAOYSA-N methoxycyclopropane Chemical compound COC1CC1 ZUVAACFIEPYYOP-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- BAZRWWGASYWYGB-UHFFFAOYSA-N n-[4-(3-aminopiperidin-1-yl)-5-bromo-1h-pyrrolo[2,3-b]pyridin-3-yl]cyclopropanecarboxamide Chemical compound C1C(N)CCCN1C1=C(Br)C=NC2=C1C(NC(=O)C1CC1)=CN2 BAZRWWGASYWYGB-UHFFFAOYSA-N 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000002411 thermogravimetry Methods 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562121396P | 2015-02-26 | 2015-02-26 | |
| US62/121,396 | 2015-02-26 | ||
| PCT/US2016/019904 WO2016138458A1 (en) | 2015-02-26 | 2016-02-26 | Crystalline forms of a pyrrolopyridine compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017133093A true RU2017133093A (ru) | 2019-03-26 |
| RU2017133093A3 RU2017133093A3 (https=) | 2019-08-23 |
Family
ID=55521844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017133093A RU2017133093A (ru) | 2015-02-26 | 2016-02-26 | Кристаллические формы соединения пирролопиридина |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20160251350A1 (https=) |
| EP (1) | EP3262042A1 (https=) |
| JP (1) | JP2018506562A (https=) |
| KR (1) | KR20170118762A (https=) |
| CN (1) | CN107406447A (https=) |
| AR (1) | AR103801A1 (https=) |
| AU (1) | AU2016225070A1 (https=) |
| BR (1) | BR112017018230A2 (https=) |
| CA (1) | CA2976665A1 (https=) |
| CL (1) | CL2017002180A1 (https=) |
| CO (1) | CO2017009662A2 (https=) |
| CR (1) | CR20170439A (https=) |
| HK (1) | HK1246786A1 (https=) |
| IL (1) | IL254115A0 (https=) |
| MA (1) | MA41599A (https=) |
| MX (1) | MX2017010888A (https=) |
| PE (1) | PE20171327A1 (https=) |
| PH (1) | PH12017501532A1 (https=) |
| RU (1) | RU2017133093A (https=) |
| SG (1) | SG11201706824TA (https=) |
| WO (1) | WO2016138458A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115385871A (zh) * | 2019-01-29 | 2022-11-25 | 沪亚生物国际有限公司 | 舒欣啶盐 |
| EP3923948A4 (en) * | 2019-02-12 | 2022-11-16 | Impact Biomedicines, Inc. | CRYSTALLINE SHAPES OF A JAK2 INHIBITOR |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| US8481557B2 (en) * | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| ES2621857T3 (es) * | 2010-11-16 | 2017-07-05 | Array Biopharma, Inc. | Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1 |
| KR102325163B1 (ko) * | 2013-08-22 | 2021-11-11 | 제넨테크, 인크. | 화합물의 제조 방법 |
| WO2015027090A1 (en) * | 2013-08-22 | 2015-02-26 | Genentech, Inc. | Intermediates and processes for preparing compounds |
-
2016
- 2016-02-25 MA MA041599A patent/MA41599A/fr unknown
- 2016-02-26 RU RU2017133093A patent/RU2017133093A/ru not_active Application Discontinuation
- 2016-02-26 AR ARP160100511A patent/AR103801A1/es unknown
- 2016-02-26 AU AU2016225070A patent/AU2016225070A1/en not_active Abandoned
- 2016-02-26 HK HK18106266.4A patent/HK1246786A1/zh unknown
- 2016-02-26 SG SG11201706824TA patent/SG11201706824TA/en unknown
- 2016-02-26 CR CR20170439A patent/CR20170439A/es unknown
- 2016-02-26 PE PE2017001459A patent/PE20171327A1/es unknown
- 2016-02-26 KR KR1020177023996A patent/KR20170118762A/ko not_active Withdrawn
- 2016-02-26 EP EP16709228.7A patent/EP3262042A1/en not_active Withdrawn
- 2016-02-26 WO PCT/US2016/019904 patent/WO2016138458A1/en not_active Ceased
- 2016-02-26 BR BR112017018230A patent/BR112017018230A2/pt not_active Application Discontinuation
- 2016-02-26 MX MX2017010888A patent/MX2017010888A/es unknown
- 2016-02-26 CN CN201680011960.5A patent/CN107406447A/zh active Pending
- 2016-02-26 US US15/054,611 patent/US20160251350A1/en not_active Abandoned
- 2016-02-26 JP JP2017545269A patent/JP2018506562A/ja not_active Withdrawn
- 2016-02-26 CA CA2976665A patent/CA2976665A1/en not_active Abandoned
-
2017
- 2017-08-23 IL IL254115A patent/IL254115A0/en unknown
- 2017-08-24 PH PH12017501532A patent/PH12017501532A1/en unknown
- 2017-08-25 CL CL2017002180A patent/CL2017002180A1/es unknown
- 2017-09-25 CO CONC2017/0009662A patent/CO2017009662A2/es unknown
- 2017-11-08 US US15/806,650 patent/US20180282324A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CL2017002180A1 (es) | 2018-03-16 |
| KR20170118762A (ko) | 2017-10-25 |
| HK1246786A1 (zh) | 2018-09-14 |
| PE20171327A1 (es) | 2017-09-12 |
| WO2016138458A1 (en) | 2016-09-01 |
| IL254115A0 (en) | 2017-10-31 |
| AR103801A1 (es) | 2017-06-07 |
| SG11201706824TA (en) | 2017-09-28 |
| PH12017501532A1 (en) | 2018-02-05 |
| MA41599A (fr) | 2018-01-02 |
| AU2016225070A1 (en) | 2017-09-07 |
| US20160251350A1 (en) | 2016-09-01 |
| US20180282324A1 (en) | 2018-10-04 |
| BR112017018230A2 (pt) | 2018-04-17 |
| JP2018506562A (ja) | 2018-03-08 |
| EP3262042A1 (en) | 2018-01-03 |
| CR20170439A (es) | 2018-01-08 |
| MX2017010888A (es) | 2017-12-15 |
| CN107406447A (zh) | 2017-11-28 |
| CO2017009662A2 (es) | 2018-02-28 |
| RU2017133093A3 (https=) | 2019-08-23 |
| CA2976665A1 (en) | 2016-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022058395A5 (https=) | ||
| EP4129295A1 (en) | Pharmaceutical composition for prevention or treatment of cancers associated with kras mutation | |
| KR101877187B1 (ko) | 치환된 다이하이드로이소퀴놀린온 화합물 | |
| RU2650895C2 (ru) | Соединения замещенных пиразолонов и способы использования | |
| KR101546693B1 (ko) | 치환된 퀴놀린 화합물 및 그 사용 방법 | |
| JP3649395B2 (ja) | 縮合ヘテロアリール誘導体 | |
| US8546413B2 (en) | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors | |
| JP2023550466A (ja) | Ｐｒｍｔ５阻害剤としての三環式カルボキサミド誘導体 | |
| KR101668931B1 (ko) | 항종양제의 효과 증강제 | |
| JPWO2020236948A5 (https=) | ||
| KR102646470B1 (ko) | 헤테로시클릭 화합물 | |
| CN105712991A (zh) | 7-氮杂吲哚衍生物 | |
| AU2019218186B2 (en) | Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof | |
| JP2018501315A5 (https=) | ||
| TW202003507A (zh) | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 | |
| AU2018380132A1 (en) | Tubulin inhibitors | |
| WO2018233620A1 (zh) | SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途 | |
| CN114206883A (zh) | 氧代吡啶稠环衍生物及包含该衍生物的药物组合物 | |
| JP2014532751A5 (https=) | ||
| JP2019500380A (ja) | ヒストンデメチラーゼ阻害剤 | |
| CN110642910B (zh) | 胸苷衍生物及其制备方法和用途 | |
| CN116113416A (zh) | 四环类衍生物、其制备方法和其医药上的用途 | |
| JP2018535980A (ja) | チエノ−ピリミジン誘導体およびその使用 | |
| CN110759963A (zh) | 一种稠环类化合物及其制备方法和用途 | |
| CN103313599A (zh) | 取代的4-(芳基氨基)硒吩并嘧啶化合物及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20191211 |